Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017

Date: August 16, 2017
Pages: 163
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AC264F954CDEN
Leaflet:

Download PDF Leaflet

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 10, 8, 15, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.

Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Attention Deficit Hyperactivity Disorder (ADHD) - Overview
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
4P-Pharma SAS
Aevi Genomic Medicine Inc
Alcobra Ltd
Amarantus Bioscience Holdings Inc
APeT Holding BV
BCWorld Pharm Co Ltd
BioHealthonomics Inc
Cingulate Therapeutics LLC
Collegium Pharmaceutical Inc
Curemark LLC
DURECT Corp
Eli Lilly and Company
H. Lundbeck A/S
Heptares Therapeutics Ltd
Highland Therapeutics Inc
KemPharm Inc
Luc Therapeutics Inc
Merck & Co Inc
Neos Therapeutics Inc
NeuroDerm Ltd
Novartis AG
Noven Pharmaceuticals Inc
Otsuka Pharmaceutical Co Ltd
P2D Bioscience
Reviva Pharmaceuticals Inc
Shire Plc
SK Biopharmaceuticals Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Taisho Pharmaceutical Holdings Co Ltd
Tris Pharma Inc
Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles
(nicotine + opipramol hydrochloride) - Drug Profile
4-P003 - Drug Profile
amfetamine XR - Drug Profile
BCWPE-003 - Drug Profile
BNC-375 - Drug Profile
CB-8411 - Drug Profile
centanafadine SR - Drug Profile
CM-4612 - Drug Profile
dasotraline hydrochloride - Drug Profile
dexmethylphenidate hydrochloride - Drug Profile
dextroamphetamine - Drug Profile
dextroamphetamine - Drug Profile
dextroamphetamine IR - Drug Profile
dextroamphetamine MR - Drug Profile
edivoxetine hydrochloride - Drug Profile
eltoprazine - Drug Profile
fasoracetam - Drug Profile
histamine dihydrochloride - Drug Profile
HTL-1071 - Drug Profile
INV-107 - Drug Profile
KP-415 CR - Drug Profile
KP-484 - Drug Profile
levofacetoperane - Drug Profile
lisdexamfetamine dimesylate - Drug Profile
mazindol CR - Drug Profile
methylphenidate ER - Drug Profile
methylphenidate hydrochloride MR - Drug Profile
methylphenidate hydrochloride SR - Drug Profile
modafinil - Drug Profile
molindone hydrochloride ER - Drug Profile
niacinamide CR - Drug Profile
NLS-4 - Drug Profile
NLS-8 - Drug Profile
P-001 - Drug Profile
PBF-509 - Drug Profile
PD-2005 - Drug Profile
PD-3044 - Drug Profile
PFR-08001 ER - Drug Profile
PFR-8026 - Drug Profile
RP-5063 - Drug Profile
SERx-480 - Drug Profile
SKL-ADHD - Drug Profile
Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile
Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder - Drug Profile
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile
Synthetic Peptide to Antagonize D2 for ADHD - Drug Profile
TAH-9901 - Drug Profile
TRN-110 - Drug Profile
TS-141 - Drug Profile
Vaccine for CNS Disorders - Drug Profile
viloxazine hydrochloride ER - Drug Profile
vortioxetine hydrobromide - Drug Profile
VU-0238429 - Drug Profile
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Novartis AG, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2017 (Contd.1), H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2017 (Contd.2), H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H2 2017 (Contd.3), H2 2017
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

4P-Pharma SAS
Aevi Genomic Medicine Inc
Alcobra Ltd
Amarantus Bioscience Holdings Inc
APeT Holding BV
BCWorld Pharm Co Ltd
BioHealthonomics Inc
Cingulate Therapeutics LLC
Collegium Pharmaceutical Inc
Curemark LLC
DURECT Corp
Eli Lilly and Company
H. Lundbeck A/S
Heptares Therapeutics Ltd
Highland Therapeutics Inc
KemPharm Inc
Luc Therapeutics Inc
Merck & Co Inc
Neos Therapeutics Inc
NeuroDerm Ltd
Novartis AG
Noven Pharmaceuticals Inc
Otsuka Pharmaceutical Co Ltd
P2D Bioscience
Reviva Pharmaceuticals Inc
Shire Plc
SK Biopharmaceuticals Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Taisho Pharmaceutical Holdings Co Ltd
Tris Pharma Inc
Skip to top


Ask Your Question

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: